Palisade Bio, Inc. · NASDAQ:PALI
Palisade Bio — Seneca Biopharma — Investor Presentation (February 2020)
14 slides from Palisade Bio's investor presentation, Feb 24, 2020
Slide 1: Seneca Biopharma Partnering Opportunities for CNS Diseases
Seneca Biopharma (NASDAQ:SNCA) Partnering Opportunities for CNS Diseases
Slide 2: Summary of Assets and Opportunity Seeking Partnership & Business Development
SUMMARY OF ASSETS AND OPPORTUNITY SEEKING PARTNERSHIP & BUSINESS DEVELOPMENT OPPORTUNITIES ALS & SCI S T RO K E ALLOGENEIC OFF THE SHELF CELL THERAPY CLINICAL STAGE: ALS and Chronic Stroke (Phase II), Spinal Cord Injury (Phase I) ASSETS: First - in - class stem cell - based treatments for neurologic
Slide 3: Neural Stem Cell Platform & IP Summary
o Regeneration of damaged neural tissue SENECA BIOPHARMA: NEURAL STEM CELL PLATFORM & IP SUMMARY PRODUCT o Allogeneic human neural stem cells: long - lasting therapeutic, requires temporary immune suppression o Committed neural lineage; CNS restricted; differentiate into functional neurons and glia
Slide 4: Pipeline: Allogeneic, Off-the-Shelf Cell Therapy: 3 CNS Indications
Indication Preclinical Phase I Phase II Phase III Amyotrophic Lateral Sclerosis (ALS) Chronic Ischemic Stroke Chronic Spinal Cord Injury FDA MEETING: March 2020 CONTROLLED STUDY READOUT: Q4 2020 PHASE I STUDY COMPLETED: Q4 2019 NSI - 566 PIPELINE: ALLOGENEIC, OFF - THE - SHELF CELL THERAPY: 3 CNS IN
Slide 5: Ischemic Stroke: Multi-Billion-Dollar Global Opportunity with Few Competitors
ISCHEMIC STROKE: MULTI - BILLION - DOLLAR GLOBAL OPPORTUNITY WITH FEW COMPETITORS ISCHEMIC STROKE OPPORTUNITY o Stroke is the most common cause of disability in the United States, most common cause of death in China (CN); ~75% of stroke cases are ischemic stroke o Estimated stroke survivor populatio
Slide 6: Chronic Stroke: Phase I Data at 12/24 Months
6 Zhang et al., 2019, Stem Cells Transl. Med. 8(10): 999 – 1007 Engraftment over 24 Months: NSI - 566 produce neurotrophic environment that regenerates tissue at infarct site BA SE L I NE 6 MONTHS 12 MONTHS 24 MONTHS ONE - TIME ADMINISTRATION OF 12 - 72 MILLION CELLS: o Direct injections into the le
Slide 7: ALS: $1B+ Opportunity
ALS: $1B+ OPPORTUNITY FOR NSI - 566 ALS OPPORTUNITY o 53,000 prevalent cases in seven major markets (US, 5EU, Japan) o 5,600 ALS patients newly diagnosed in United States annually o 50% increase in developing World expected 2015 - 2040 o Limited treatment options with poor efficacy o US NSI - 566 ad
Slide 8: ALS: Evidence of Efficacy Compared to Historical Controls
o NSI - 566 treated patients showed preliminary evidence of clinical benefit compared to historical controls o Autopsies of deceased trial participants revealed persistent graft in all patients evaluated: up to 2.5 yrs. after treatment AND 1.75 yrs. after immunosuppression ended NSI - 566 AND ALS: E
Slide 9: Chronic Spinal Cord Injury: Further Upside Potential
CHRONIC SPINAL CORD INJURY: 3 RD INDICATION PRESENTS FURTHER UPSIDE POTENTIAL SCI OPPORTUNITY o 17K cases in United States annually and between 250K - 500K globally o Managed symptomatically, little to no spontaneous improvement after initial stage o No therapeutic to restore neurological function,
Slide 10: SCI: Effect in Monkey Model and Potential Benefit in Humans
10 NSI - 566 AND SCI: EFFECT OF NSI - 566 IN MONKEY MODEL AND POTENTIAL BENEFIT IN HUMANS Rosenzweig et al., 2018, Nat Med. 24(4): 484 - 490 o Graft - derived neurons integrate, extend long processes and form synaptic connections with healthy host neurons o Grafts confer improvement in motor functio
Slide 11: Kenneth Carter, Ph.D. and Matthew Kalnik, Ph.D.
KENNETH CARTER, PH.D. Executive Chairman o Led public and private biotechnology companies as CEO and/or Chairman o Co - founder of Avalon, Noble, NeoDiagnostics, NexImmune, Iterion, and others o Extensive early - stage drug development experience o CEO of Avalon Pharmaceuticals 10 years including IP
Slide 12: Promising Partnering Opportunity
PROMISING PARTNERING OPPORTUNITY o First - in - class stem cell - based treatments for neurological diseases o Unmet medical needs in CNS diseases: ALS, chronic stroke, chronic spinal cord injury o Strong fundamental science and technology platform, significant development to date o Existing global
Slide 13: Transaction Summary & Timeline
TRANSACTION SUMMARY & TIMELINE SUMMARY o Initiating process for asset sale, out license, global development partnerships o Open to various structures: Investment, license/co - development, asset sale, or JV TIMELINE o Q1 2020: Initial outreach to interested parties and initial due diligence o Q2 202
Slide 14: Thank You / Contact Information
THANK YOU CONTACT INFORMATION: Kenneth Carter, PhD Executive Chairman k c arter @ senecabi o .com 14
Seneca Biopharma — Investor Presentation (February 2020) on 6ix